-
公开(公告)号:EP4366759A1
公开(公告)日:2024-05-15
申请号:EP22835557.4
申请日:2022-07-04
申请人: Mapi Pharma Ltd.
CPC分类号: A61P3/04 , A61P3/10 , A61K38/26 , A61K9/0024 , A61K9/1647
-
-
公开(公告)号:EP3536333A1
公开(公告)日:2019-09-11
申请号:EP18205308.2
申请日:2010-08-19
申请人: Mapi Pharma Ltd.
发明人: MAROM, Ehud , RUBNOV, Shai
摘要: The present invention provides long acting parenteral pharmaceutical compositions comprising a therapeutically effective amount of glatiramer. In particular, the present invention provides a long acting pharmaceutical composition comprising a therapeutically effective amount of glatiramer acetate in depot form suitable for administering at a medically acceptable location in a subject in need thereof. The depot form is suitable for subcutaneous or intramuscular implantation or injection.
-
公开(公告)号:EP4252849A3
公开(公告)日:2023-11-01
申请号:EP23173177.9
申请日:2017-08-09
申请人: Mapi Pharma Ltd.
发明人: BLEICH KIMELMAN, Nadav , RUBNOV, Shai , MAROM, Ehud , DANON, Uri
IPC分类号: A61K38/02 , A61K38/10 , A61K38/16 , A61K9/00 , A61K9/16 , A61K9/50 , A61K47/32 , A61K47/36 , A61P25/00 , A61P25/28
摘要: The present invention provides compositions and methods of use thereof for treating or ameliorating multiple sclerosis (MS) by administering a depot formulation comprising 40 mg glatiramer acetate intramuscularly to the MS patient.
-
公开(公告)号:EP4171613A1
公开(公告)日:2023-05-03
申请号:EP21833944.8
申请日:2021-04-26
申请人: Mapi Pharma Ltd.
IPC分类号: A61K38/26 , A61K9/00 , A61K9/16 , C07K14/605 , A61P3/10
-
公开(公告)号:EP3506921A1
公开(公告)日:2019-07-10
申请号:EP17845658.8
申请日:2017-08-09
申请人: Mapi Pharma Ltd
发明人: MAROM, Ehud , BLEICH KIMELMAN, Nadav , DANON, Uri , RUBNOV, Shai
-
公开(公告)号:EP4252849A2
公开(公告)日:2023-10-04
申请号:EP23173177.9
申请日:2017-08-09
申请人: Mapi Pharma Ltd.
发明人: BLEICH KIMELMAN, Nadav , RUBNOV, Shai , MAROM, Ehud , DANON, Uri
IPC分类号: A61P25/28
摘要: The present invention provides compositions and methods of use thereof for treating or ameliorating multiple sclerosis (MS) by administering a depot formulation comprising 40 mg glatiramer acetate intramuscularly to the MS patient.
-
-
-
-
-
-